Skip to navigation menu Skip to content
Clinical Trial Search block Test

The Effects of Tirzepatide in Young adults with Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity

Tirzepatide

What is the goal of the study?

To evaluate the percent change in weight and BMI from baseline during 48 weeks of treatment with tirzepatide in young adults with Prader-Willi Syndrome (PWS), hypothalamic obesity (HO), general non-syndromic obesity (GNSO) and obesity

Who can participate in the study?

Everyone

Study Team: